Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc.APUS · Entity 8263 | Director · Chairman and CMO | October 15, 2025 | October 17, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Apimeds Pharmaceuticals US, Inc.
Report date October 15, 2025 · Filed October 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.92 · Expires 2035-10-15 | Direct | 3,000 |
Reported balance
After 2025-10-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-10-15 · Grant · Acquired 3,000 · Balance 3,000 F1: The shares of common stock subject to the option shall vest in quarterly installments beginning October 1, 2025, such that the award shall be fully vested after three years subject to the reporting person's service to the issuer continuing through and on each vesting date. This option is not exercisable until stockholder approval is obtained to approve an amendment to the issuer's incentive plan (the "Plan") to increase the number of shares of common stock available for issuance under the Plan. The shares of common stock subject to the option shall vest in full upon the occurrence of a Change in Control, as defined in the Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock subject to the option shall vest in quarterly installments beginning October 1, 2025, such that the award shall be fully vested after three years subject to the reporting person's service to the issuer continuing through and on each vesting date. This option is not exercisable until stockholder approval is obtained to approve an amendment to the issuer's incentive plan (the "Plan") to increase the number of shares of common stock available for issuance under the Plan. The shares of common stock subject to the option shall vest in full upon the occurrence of a Change in Control, as defined in the Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 15, 2025 Filed Oct 17, 2025 23:03 UTC | Apimeds Pharmaceuticals US, Inc. APUS · Entity 8263 | GrantStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0002040022-25-000002 · primary_doc.xml · derivative · entry 1 Kim Christopher · CIK 0002040022 · Director · Chairman and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock, par value $0.01 per share · 3,000 shares Expires 2035-10-15 F1 · derivative.exercise_date: The shares of common stock subject to the option shall vest in quarterly installments beginning October 1, 2025, such that the award shall be fully vested after three years subject to the reporting person's service to the issuer continuing through and on each vesting date. This option is not exercisable until stockholder approval is obtained to approve an amendment to the issuer's incentive plan (the "Plan") to increase the number of shares of common stock available for issuance under the Plan. The shares of common stock subject to the option shall vest in full upon the occurrence of a Change in Control, as defined in the Plan. Read SEC document |
| May 16, 2025 Filed May 20, 2025 21:00 UTC | Apimeds Pharmaceuticals US, Inc. APUS · Entity 8263 | GrantCommon Stock, par value $0.01 per share | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001474506-25-000100 · primary_doc.xml · nonDerivative · entry 1 Kim Christopher · CIK 0002040022 · Director · Chairman and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 277,500 Read SEC document |
| May 14, 2025 Filed May 15, 2025 22:48 UTC | Apimeds Pharmaceuticals US, Inc. APUS · Entity 8263 | PurchaseCommon Stock, par value $0.01 per share | 7,730 | $1.86 | $14,377.80 |
DisclosureSEC source: 0001474506-25-000096 · primary_doc.xml · nonDerivative · entry 2 Kim Christopher · CIK 0002040022 · Director · Chairman and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,500 F1 · price: The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Apimeds Pharmaceuticals US, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2)-(3) to this Form 4. F3 · price: These shares were sold in multiple transactions at prices ranging from $1.84 to $1.89, inclusive. Read SEC document |
| May 13, 2025 Filed May 15, 2025 22:48 UTC | Apimeds Pharmaceuticals US, Inc. APUS · Entity 8263 | PurchaseCommon Stock, par value $0.01 per share | 19,770 | $1.82 | $35,981.40 |
DisclosureSEC source: 0001474506-25-000096 · primary_doc.xml · nonDerivative · entry 1 Kim Christopher · CIK 0002040022 · Director · Chairman and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,770 F1 · price: The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Apimeds Pharmaceuticals US, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2)-(3) to this Form 4. F2 · price: These shares were sold in multiple transactions at prices ranging from $1.75 to $1.86, inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.